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An association between occupational exposures
of inhaled particulates and autoimmunity was
postulated as early as 1914, when Bramwell
(1914) reported increased frequency of diffuse
scleroderma (SSc) in stone masons. Although
genetic factors undoubtedly exist that affect the
development of systemic autoimmune diseases
(SAIDs) in certain individuals, the concor-
dance of SAIDs among identical twins is only
25–40%, suggesting that environmental fac-
tors play a substantial role (Powell et al. 1999).
Indeed, several environmental agents are impli-
cated in triggering or accelerating SAIDs,
including mercury, iodine, vinyl chloride, cer-
tain pharmaceuticals, and crystalline silica.
However, much more research is needed to
determine the mechanisms and epidemiology
linking exposures to development of SAIDs.
There is considerable epidemiologic evidence
supporting the hypothesis that occupational
silica exposure is associated with a variety of
SAIDs, including SSc, rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE),
glomerulonephritis, and small vessel vasculitis
(Koeger et al. 1995; Parks et al. 1999, 2002;
Powell et al. 1999; Steenland and Goldsmith
1995). Research regarding asbestos exposure
and SAIDs has been much more limited.
Asbestos-related lung disease continues to
be a serious and significant problem world-
wide despite increasing awareness of health
hazards of asbestos inhalation. Asbestos expo-
sure is associated with various lung conditions,
including ﬁbrosis, pleural plaques, and cancer.
Although the exact mechanisms leading to the
progression of these conditions have not been
fully explained, there is evidence that some of
the lung abnormalities seen with both asbestos
and silica exposures are immunologically
mediated (Hamilton et al. 1996; Holian et al.
1997; Perkins et al. 1993). Nevertheless, it is
unclear how these innate immune responses
might translate to speciﬁc humoral responses.
Increased serum immunoglobulins (Ig), posi-
tive antinuclear antibody (ANA) tests, and
immune complexes have been reported in
small cohorts of individuals exposed to
asbestos (Lange 1980; Nigam et al. 1993;
Pfau et al. 2005; Zerva et al. 1989), but no
comprehensive study has been undertaken to
assess the association between asbestos expo-
sure and autoimmune disease.
Our major objective, therefore, is to estab-
lish whether such an association exists, and the
community of Libby, Montana, provides a
unique opportunity to investigate this ques-
tion. Individuals in this population experi-
enced signiﬁcant exposures that occurred as a
result of asbestos-contaminated vermiculite
mining near the community. From the early
1920s to 1990, the world’s largest vermiculite
deposits, located near Libby, were mined and
processed. Vermiculite is a silicate mineral
with unique properties and numerous com-
mercial applications (Lockey 1984). The
ﬁbrous minerals contaminating Libby vermi-
culite have been characterized as both regu-
lated asbestos ﬁbers (e.g., tremolite and other
amphibole forms) and unregulated ﬁbers (e.g.,
winchite and richterite) (Meeker et al. 2003).
The various mining, transportation, and pro-
cessing activities as well as the personal and
commercial use of vermiculite in the commu-
nity have led to widespread environmental
exposures in the Libby area with this asbestos-
contaminated vermiculite. Potential asbestos
exposures in this community have been docu-
mented not only in the miners but also in their
family members as well as anyone who used
the vermiculite or played near the mine tailings
(Dixon et al. 1985). A mortality study in this
community found more than 40-fold increases
in standardized mortality ratios for asbestosis,
and elevated mortality also was observed for
malignant neoplasm of respiratory and
intrathoracic organs (Horton et al., in press).
Recently, the Agency for Toxic Substances
and Disease Registry (ATSDR) conducted an
extensive screening program of > 7,300 indi-
viduals from this community (Peipins et al.
2003). The initial results of this screening
program identiﬁed various routes of exposure
in the community and how those routes of
exposure were associated with abnormalities
on chest radiographs (Peipins et al. 2003). In
addition, when the ATSDR performed its
screening in Libby during 2000–2001, 494
(6.7%) participants indicated that they had
been diagnosed with SLE, SSc, or RA
(Noonan et al. 2005). By comparison, a
prevalence of < 1% for these three conditions
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OBJECTIVE: To explore the potential association between asbestos exposure and risk of autoimmune
disease, we conducted a case–control study among a cohort of 7,307 current and former residents
of Libby, Montana, a community with historical occupational and environmental exposure to
asbestos-contaminated vermiculite.
METHODS: Cases were deﬁned as those who reported having one of three systemic autoimmune
diseases (SAIDs): systemic lupus erythematosus, scleroderma, or rheumatoid arthritis (RA).
Controls were randomly selected at a 3:1 ratio from among the remaining 6,813 screening partici-
pants using frequency-matched age and sex groupings.
RESULTS: The odds ratios (ORs) and 95% confidence intervals (CIs) for SAIDs among those
≥ 65 years of age who had worked for the vermiculite mining company were 2.14 (95% CI,
0.90–5.10) for all SAIDs and 3.23 (95% CI, 1.31–7.96) for RA. In this age group, exposure to
asbestos while in the military was also an independent risk factor, resulting in a tripling in risk.
Other measures of occupational exposure to vermiculite indicated 54% and 65% increased risk for
SAIDs and RA, respectively. Those who had reported frequent contact with vermiculite through
various exposure pathways also demonstrated elevated risk for SAIDs and RA. We found increasing
risk estimates for SAIDs with increasing numbers of reported vermiculite exposure pathways
(p < 0.001).
CONCLUSION: These preliminary ﬁndings support the hypothesis that asbestos exposure is associ-
ated with autoimmune disease. Reﬁned measurements of asbestos exposure and SAID status among
this cohort will help to further clarify the relationship between these variables. 
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http://dx.doi.org/ [Online 30 May 2006]combined would be expected based on pooled
estimates from 43 prevalence studies
(Jacobson et al. 1997). In the present study,
we take these data a step further by exploring
the association of these systemic autoimmune
conditions with various parameters of asbestos
and/or vermiculite exposure using a nested
case–control approach.
Materials and Methods
All human subjects provided informed con-
sent for this study under a protocol approved
by the institutional review board for the
Centers for Disease Control and Prevention.
The details of the ATSDR screening program
are described elsewhere (Peipins et al. 2003).
Brieﬂy, individuals were eligible for the screen-
ing program if they had resided, worked,
attended school, or participated in other activ-
ities in the Libby area for at least 6 months
before 31 December 1990. All screening par-
ticipants who were ≥ 18 years of age and not
pregnant (n = 6,668) were offered chest radio-
graphs. Two independent B readers evaluated
the radiographs for each subject for pleural
and parenchymal abnormalities. If these two
readers disagreed regarding the presence of
pneumoconiosis for a subject, a third reader
was used to adjudicate the difference.
Participants were classified as “positive” for
pleural or parenchymal abnormalities if at least
two of three B readers observed this type of
abnormality on chest radiographs. Participants
also received spirometry testing and were con-
sidered to have abnormal ﬁndings if they had
a forced vital capacity (FVC) < 80% predicted
and a ratio of 1 sec forced expiratory volume
(FEV1) to FVC that is ≥ 70% predicted. Data
on exposure to asbestos-contaminated vermi-
culite were based on occupational, residential,
and recreational histories collected during in-
person interviews. Demographic variables and
data on other potential covariates were also
collected by in-person interview.
This study was conducted in two phases.
The initial characterization of cases (n = 494)
with SAIDs were those participants who, dur-
ing the 2000–2001 ATSDR screening pro-
gram, responded afﬁrmatively to the question
“Have you ever had rheumatoid arthritis, scle-
roderma, or lupus?” Potential controls were
those screening participants who answered
negatively to this question. Controls were ran-
domly selected from within strata of sex and
10-year age groups at a 3:1 control-to-case
ratio (n = 1,482) (Figure 1).
The initial screening question on SAIDs
was collected only to identify screening partici-
pants with health conditions that could have an
impact on pulmonary function or ﬁbrosis. The
second phase of this study involved a mailed
questionnaire to confirm the original self-
reports of SAIDs and to identify which of the
three conditions the potential cases were report-
ing. The follow-up survey was mailed to all 494
potential SAID cases for whom current
addresses were available. The follow-up survey
queried potential cases on whether or not they
still considered themselves to have one of the
three indicated SAIDs, which SAID(s) they
had, whether or not their SAIDs were diag-
nosed by a physician, and whether or not they
were taking medication or other treatment for
their condition. For those reporting RA, addi-
tional questions were asked to conﬁrm the type
of arthritis on which they were reporting (i.e.,
RA, osteoarthritis, or general arthritis). This fol-
low-up survey was approved by the University
of Montana investigational review board.
Analyses were conducted using uncondi-
tional logistic regression using SAS (version 9;
SAS Institute Inc., Cary, NC). The presence or
absence of SAIDs or a specific autoimmune
disease in the postmailing analysis was used as
the dependent variable. The various pathways
of exposure to vermiculite and/or asbestos were
considered as the main independent variables
of interest. Test for trend with increasing num-
bers of exposure pathways was assessed using
the Cochran-Armitage test. Potential con-
founders included indications of restrictive
spirometry and the presence of pleural or
parenchymal abnormalities. These pulmonary
features were the main outcomes of the
ATSDR screening program and could be inde-
pendently associated with both asbestos expo-
sure and biomarkers of autoimmunity (Pfau
et al. 2005). For the ﬁnal unconditional logis-
tic regression models, all vermiculite/asbestos
exposure pathways and other potential risk fac-
tors were considered. Criteria for inclusion in
the ﬁnal model included statistical signiﬁcance
of the explanatory variable (p < 0.10), the pres-
ence of a confounding effect on other variables,
and the ﬁt of the model.
Results
The distribution of SAID subjects for selected
characteristics are presented in Table 1.
Among the 494 subjects responding positively
to the original SAID screening question,
287 (58%) were women. More than 75% of
SAID subjects lived in Libby for at least
15 years. Follow-up mailed questionnaires
were sent to all 494 subjects who were classi-
ﬁed as having SAIDs in the initial analysis. Of
these, 208 (43%) participants responded.
Among those responding, 161 participants
conﬁrmed that they had a physician-diagnosed
SAID. The proportional distribution of those
reporting physician-diagnosed SAIDs was simi-
lar to the original 494 who reported SAIDs
with regard to sex, age, smoking history, and
years lived in Libby (Table 1). Among those
Noonan et al.
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Figure 1. Case and control selection from initial screening population. DPHHS, Montana Department of
Public Health and Human Services. Lupus refers to SLE.
7,307 current and former Libby
residents who participated in
the ATSDR/DPHHS screening
program
Control selection frequency
matched by age and sex
to cases
“Have you ever had
RA, SSc, lupus?” 6,813 potential controls
494 potential cases 1,482 controls
(3:1 control:case ratio)
Initial
analysis
“Has a physician
diagnosed you with:
RA?
SSc?
Lupus?”
Responses from
mailed survey
(n = 208; 42%)
161 self-confirmed SAID cases
129 self-confirmed RA cases 1,482 controls Secondary
analysis
No
Yes
Yesreporting physician-diagnosed SAIDs, 129 par-
ticipants indicated that they had physician-
diagnosed RA, 70% of whom took medication
for RA. Thirty participants indicated that they
had physician-diagnosed SLE, 63% of whom
took medication for SLE. Another four partici-
pants indicated that they had SSc, and two of
those took medication for SSc.
Considering the initial case group
(n = 494), the distribution of years of resi-
dence was not different for cases and controls
(χ2 = 0.57, p < 0.90). Current and former
smokers were more common among SAID
subjects [odds ratio (OR) = 1.72; 95% conﬁ-
dence interval (CI), 1.22–2.44]. SAIDs also
were associated with parenchymal abnormali-
ties and with restrictive spirometry but not
strongly with pleural abnormalities (Table 2).
These associations remained consistent when
evaluating those reporting physician-diagnosed
SAIDs (n = 161) (Table 2). Both restrictive
spirometry and parenchymal abnormalities as
well as current or former smoking were
included in the unconditional logistic regres-
sion models for vermiculite/asbestos exposure
and risk of SAIDs.
The adjusted ORs for various potential
exposure pathways to vermiculite and asbestos
and risk of SAIDs are presented in Table 3.
Previous occupation with the mining com-
pany yielded no overall increased risk for
SAIDs (OR = 1.03; 95% CI, 0.69–1.58).
However, we observed elevated ORs for pre-
vious occupation with the mining company
among those ≥ 65 years of age at the time of
the screening, particularly for RA. Among
other occupational vermiculite exposures,
“dust or vermiculite exposure at jobs other
than W.R. Grace/Zonolite” was the most
consistently associated with reporting of any
SAID or RA speciﬁcally. Among other occu-
pations with potential exposure to asbestos,
only those reporting asbestos exposure in the
military were at increased risk for SAIDs and
RA, yielding ORs of 1.70 and 2.11, respec-
tively. Several reported activities or experi-
ences were associated with increased risk of
any SAID or RA speciﬁcally. Considering all
exposure pathways collectively, increasing
opportunities for vermiculite and/or asbestos
exposure yielded increasing risk estimates for
SAIDs and RA (Table 4). Although the num-
ber of SLE cases was too small (n = 30) to
evaluate for trend as in Table 4, we did
observe an elevated risk for SLE among those
with more than three pathways of exposure
versus those with three or fewer pathways of
exposure (OR = 4.45; 95% CI, 1.24–16.00).
We did not observe sufﬁcient numbers of SSc
cases to evaluate this disease by asbestos expo-
sure pathways.
Table 5 presents final unconditional
logistic regression models in which all expo-
sure pathways and other potential risk factors
were considered for their contribution to the
risk of SAIDs and RA. Because older partici-
pants had differing occupational risk factors,
we constructed models stratified by age. For
participants < 65 years of age, dust or vermi-
culite exposure at jobs other than W.R.
Grace/Zonolite was the only occupational
exposure that remained in the models for both
SAIDs and RA. For participants ≥ 65 years of
age, asbestos exposure in the military yielded
substantially elevated risk estimates for both
SAIDs and RA. For this age group, working at
W.R. Grace/Zonolite also resulted in a 3-fold
greater risk for RA. Elevated ORs were also
observed for several nonoccupational expo-
sures to vermiculite (Table 5).
Discussion
Although there is considerable epidemiologic
evidence supporting the hypothesis that occu-
pational silica exposure is associated with a
variety of SAIDs, research regarding asbestos
Asbestos exposure and autoimmune disease
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Table 1. Distribution [n (%)] of selected characteristics for participants reporting any SAID, RA, or SLE. 
Characteristic SAIDsa (n = 494) SAIDsb (n = 161) RA (n = 129) SLE (n = 30)
Sex
Male 207 (41.9) 69 (42.9) 61 (47.3) 2 (6.7)
Female 287 (58.1) 92 (57.1) 68 (52.7) 28 (93.3)
Age (years)c
17–44 69 (14.0) 18 (11.2) 15 (11.6) 5 (16.7)
45–64 258 (52.2) 97 (60.3) 80 (62.0) 21 (70.0)
≥ 65 167 (33.8) 46 (28.6) 34 (26.4) 4 (13.3)
Smoking history
Never 163 (33.1) 51 (31.9) 35 (27.3) 11 (36.7)
Ex-smoker 214 (43.4) 78 (48.8) 64 (50.0) 14 (46.7)
Current 116 (23.5) 31 (19.4) 29 (22.7) 5 (16.7)
Years lived in Libby
0.5–14 118 (23.9) 37 (22.9) 28 (21.7) 0 (0.0)
15–27 133 (26.9) 41 (25.5) 36 (27.9) 9 (30.0)
28–39 120 (24.3) 47 (29.2) 39 (30.2) 12 (40.0)
≥ 40 123 (24.9) 36 (22.4) 26 (20.2) 9 (30.0)
aSubjects responding positively to original screening question on SAIDs. bSubjects confirming physician-diagnosed
SAIDs in follow-up mailing. cAge as of 1 January 2000.
Table 3. Adjusted ORsa (95% CIs) for vermiculite/asbestos exposure and risk of any SAID or RA specifi-
cally, Libby, Montana.
Exposure pathway SAIDsb (n = 494) SAIDsc (n = 161) RA (n = 129)
Potential occupational exposure to vermiculite
Ever work for W.R. Grace/Zonolite
Age < 65 years 0.57 (0.29–1.11) 0.74 (0.29–1.91) 0.52 (0.16–1.70)
Age ≥ 65 years 1.47 (0.82–2.63) 2.14 (0.90–5.10) 3.23 (1.31–7.96)
Contract worker for W.R. Grace/Zonolite 1.29 (0.89–1.89) 1.21 (0.67–2.20) 1.29 (0.89–1.89)
Live with W.R. Grace/Zonolite workers 1.19 (0.93–1.53) 1.29 (0.88–1.90) 1.23 (0.80–1.90)
Dust or vermiculite exposure at other jobs 1.33 (1.08–1.64) 1.54 (1.10–2.15) 1.65 (1.14–2.39)
Potential occupational exposure to asbestos
Worked mixing, cutting, or spraying asbestos 1.39 (0.76–2.54) 0.47 (0.11–2.01) 0.59 (0.14–2.53)
Worked in shipyard/ship construction 1.27 (0.68–2.37) 1.23 (0.46–3.25) 1.80 (0.72–4.46)
Asbestos exposure in the military 1.05 (0.62–1.79) 1.70 (0.84–3.44) 2.11 (1.04–4.30)
Worked in construction-related jobsd 1.21 (0.79–1.84) 1.17 (0.60–2.27) 1.32 (0.66–2.65)
Worked as a brake repair person 0.87 (0.49–1.55) 0.65 (0.23–1.86) 0.61 (0.19–2.02)
Activities or experiences with potential exposure
Frequently handled vermiculite insulation 1.34 (0.99–1.82) 1.60 (1.02–2.52) 1.89 (1.17–3.04)
Used vermiculite for gardening 1.31 (1.06–1.62) 1.70 (1.19–2.43) 1.70 (1.15–2.53)
Frequently recreated near Rainey Creek Road 1.50 (1.18–1.91) 1.67 (1.15–2.43) 1.78 (1.19–2.68)
Frequently played in the vermiculite piles 1.39 (1.02–1.91) 1.85 (1.18–2.92) 2.06 (1.27–3.34)
Frequently played at the ballﬁeld near the plant 1.19 (0.95–1.49) 1.62 (1.14–2.30) 1.74 (1.18–2.55)
Frequently “popped” vermiculite 1.39 (0.96–2.02) 2.11 (1.27–3.52) 1.68 (0.92–3.05)
aAdjusted for restrictive spirometry, parenchymal abnormalities, and smoking history. bSubjects responding positively to
original screening question on SAIDs. cSubjects confirming physician-diagnosed SAIDs in follow-up mailing. dIncludes
carpenter, drywall ﬁnisher, insulator, roofer, plumber, electrician, welder, and pipe ﬁtter. 
Table 2. Association between SAIDs and positive ﬁndings for chest radiograph and pulmonary function.
Medical evaluation outcome SAIDsa (n = 494) OR (95% CI) SAIDsb (n = 161) OR (95% CI)
Pulmonary function test abnormalityc 90 1.76 (1.34–2.32) 37 2.23 (1.50–3.33)
Pleural abnormalityd 134 1.15 (0.91–1.45) 46 1.25 (0.87–1.79)
Parenchymal abnormalityd 27 2.54 (1.51–4.27) 9 2.62 (1.23–5.58)
aSubjects responding positively to original screening question on SAIDs. bSubjects confirming physician-diagnosed
SAIDs in follow-up mailing. cFVC < 80% predicted and an FEV1:FVC ratio ≥ 70% predicted. dAt least two of three B readers
observed this type of abnormality on chest radiographs.exposure and SAIDs has been much more
limited. The preliminary findings presented
here support the hypothesis that asbestos
exposure is associated with the presence of
autoimmune disease. We found increased risk
for SAIDs among those reporting occupa-
tional and environmental or recreational
exposures to vermiculite and/or asbestos.
Increased risk estimates were found for
increasing numbers of reported exposure
pathways. The risk estimates by exposure
pathway remained elevated and in some cases
increased after restricting the cases to those
who responded to a follow-up survey and con-
firmed that they had a physician-diagnosed
SAID or RA specifically. We recognize the
limitation of this approach of combining
exposure pathways of unequal intensity and
duration, but it also provides an analysis that
parallels the previously observed findings of
asbestos exposure and lung abnormalities in
this population (Peipins et al. 2003). The
multivariable analysis identiﬁed speciﬁc expo-
sure pathways that were independently associ-
ated with risk of SAIDs, including older
subjects who had worked for the mining
company. Among older participants, we also
observed increased risk estimates for SAIDs
and RA among those reporting exposure to
asbestos in the military. The risk for military
asbestos exposure was independent of the
elevated risk for previous work at W.R.
Grace/Zonolite and other Libby exposure
pathways. These findings suggested that
asbestos exposure in general rather than Libby
vermiculite exposure in particular could be
relevant to SAID etiology.
These findings were consistent with a
recent immunologic study we undertook
among a small group of volunteers from this
same Libby community (Pfau et al. 2005).
The results of that study supported the
hypothesis that increased frequency of posi-
tive ANA would be found in the Libby group
compared to an age- and sex-matched unex-
posed population in Missoula, Montana.
Among the Libby volunteers, the titers of the
positive ANAs were positively correlated with
the length of the individual’s estimated
asbestos exposure. Previous studies have meas-
ured several immune parameters in popula-
tions exposed to asbestos. Investigators in
India demonstrated increased IgG, IgA, and
positive ANAs in asbestos-exposed individu-
als, compared to controls, even in the absence
of apparent lung disease (Nigam et al. 1993).
This finding suggested that immune altera-
tions may precede the onset of asbestos-
related disease. A high frequency of positive
ANAs was also found in a Japanese group of
asbestos plant workers (Tamura et al. 1993).
Interestingly, a 3-year follow-up study of the
Japanese group showed signiﬁcant correlation
of positive ANAs with progression of disease,
leading to additional diagnoses of asbestosis in
a previously healthy group (Tamura et al.
1996). A study of Greek residents exposed to
asbestos-contaminated whitewash showed a
correlation of immune abnormalities particu-
larly in individuals with pleural plaques (Zerva
et al. 1989), whereas the Japanese study
showed a greater effect in individuals with dif-
fuse ﬁbrosis but not pleural plaques. In addi-
tion, a Polish study reported increased ANA
frequency particularly in individuals exhibiting
lung function deﬁcits (Lange 1980).
Despite some inconsistency between the
studies cited above, all of these immunologic
studies illustrate two important considera-
tions. First, asbestos exposure is clearly associ-
ated with indices of autoimmune responses.
Second, although the details vary, the auto-
immune responses appear to correlate with
asbestos-related disease, suggesting a possible
role for the autoimmune responses in the dis-
ease process. The temporal relationship among
asbestos exposure, autoimmune response, and
asbestos-related diseases is uncertain and
beyond the scope of the present study.
Nevertheless, our findings of strong associa-
tions between asbestos and/or vermiculite
exposure and risk of SAIDs remained robust
after adjusting for objectively characterized
pulmonary conditions that could be associated
with asbestos exposure.
As described previously, the initial case
group was based on those who responded
positively to a screening question about
autoimmune conditions. Asbestos exposure
and SAIDs is a relatively novel avenue of
research, so it is not expected that participants
would overreport SAIDs because of a sus-
pected association. For the same reason, we
would not expect self-reported asbestos expo-
sure to be differentially misclassified with
respect to SAID status. As a ﬁrst step toward
improving disease characterization, we con-
ducted a mailing to all participants who indi-
cated having an SAID during the initial
screening program. Of those who responded to
the mailing, almost 23% were unable to con-
ﬁrm that they had RA, SLE, or SSc. In general,
when restricting the analyses to those reporting
any physician-diagnosed SAID or RA speciﬁ-
cally, the risk estimates for several pathways of
asbestos and/or vermiculite exposure were
increased. Comparisons of risk estimates
between the original group of suspected cases
and those who reconﬁrmed diagnosis should
be made with caution, however, because both
sets of cases are based on self-report.
Given the unique circumstances of com-
munity asbestos exposure and the resulting
screening program, it is also possible that
there was a case ascertainment error that was
biased with respect to exposure. Specifically,
those with greater history of asbestos exposure
would be more likely to have lung abnormali-
ties or frank asbestos-related disease and
would have received more intensive medical
care. Better medical care could, in turn, result
in a higher likelihood of being diagnosed with
Noonan et al.
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Table 5. Final model adjusted ORs (95% CIs) for vermiculite/asbestos exposure and risk of any SAID or RA
speciﬁcally, Libby, Montana.
SAIDs RA
< 65 years ≥ 65 years < 65 years ≥ 65 years
Variable (n = 115) (n = 46) (n = 95) (n = 34)
Ever work for W.R. Grace/Zonolite —a — — 3.03 (1.17–7.82)
Dust or vermiculite exposure at other jobs 1.60 (1.07–2.38) — 1.71 (1.10–2.66) —
Asbestos exposure in the military — 2.99 (1.04–8.59) — 3.31 (1.00–10.96)
Used vermiculite for gardening 1.66 (1.09–2.53) — — 3.43 (1.34–8.76)
Frequently played in the vermiculite piles — — 1.77 (1.03–3.04) 2.75 (0.75–10.06)
Frequently “popped” vermiculite — 4.33 (1.59–11.80) — —
Restrictive spirometry 3.23 (1.91–5.47) — 3.09 (1.74–5.47) 2.02 (0.87–4.72)
Parenchymal abnormalities — 3.29 (1.31–8.25) — 2.90 (0.95–8.87)
Current or former smoker — 1.82 (0.89–3.69) 1.75 (1.09–2.82) —
χ2, p-valueb 1.195, 0.75 0.250, 0.62 2.349, 0.80 1.211, 0.88
aVariable did not enter the ﬁnal model for the given disease/age stratum. bHosmer-Lemeshow goodness-of-ﬁt test; small
p-value suggests that the ﬁtted model is not an adequate model. 
Table 4. Crude and adjusteda ORs (95% CIs) risk of any SAID or RA speciﬁcally, by number of vermiculite/
asbestos exposure pathways. 
No. of  SAIDs (n = 161) RA (n = 129)
exposure  Adjusted OR  Adjusted OR 
pathways Cases/controls OR (95% CI) Cases/controls OR (95% CI)
0 2/34 1.00 (Referent) 1.00 (Referent) 1/34 1.00 (Referent) 1.00 (Referent)
1 5/101 0.84 0.89 (0.16–4.83) 3/101 1.01 1.02 (0.10–10.23)
2–3 26/345 1.28 1.36 (0.31–6.04) 18/345 1.77 1.79 (0.23–13.93)
4–5 32/364 1.49 1.60 (0.36–7.04) 27/364 2.52 2.51 (0.33–19.18)
6+ 96/637 2.56 2.58 (0.60–11.05) 80/637 4.27 3.98 (0.53–29.66)
Trendb p < 0.001 p < 0.001
aAdjusted for restrictive spirometry, parenchymal abnormalities, and smoking history. bCochran-Armitage trend test.other conditions such as SAIDs. This concern
is somewhat tempered by the fact that pleural
abnormality, the asbestos-related condition
that has been most strongly associated with
asbestos exposure in this population, was not
associated with reporting of SAIDs.
It is also possible, but less likely, that dis-
ease status was misclassified among controls.
Controls were chosen from among those in the
cohort who responded negatively to the screen-
ing questions about autoimmune conditions,
but we did not conﬁrm the absence of disease
among these selected controls. It is possible
that some participants with SAIDs did not
understand the screening questions and were
inappropriately included in the pool of poten-
tial controls. This possibility is expected to be
of minor concern based on the low prevalence
of these conditions in the general population
(Jacobson et al. 1997).
This study could suffer from exposure
misclassiﬁcation because these measures were
based on self-reported responses as part of a
large community-based screening program.
Recall bias is a possibility, and persons with
chronic health conditions such as SAIDs
could overreport past exposure to vermiculite.
In the future, we plan to improve on exposure
characterization for this cohort, incorporating
job exposure matrices and quantitative or
semiquantitative assessment of other exposure
pathways.
In summary, these preliminary findings
provide a unique insight into the risk for
autoimmune disease among a population with
historical asbestos exposures. These results war-
rant a more comprehensive case–control study
of this population with improved disease and
exposure characterization and the incorporation
of biomarkers of genetic susceptibility.
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